Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 13/20 | 0.45 |
| ▸ | FNTB | P49356 | 13/20 | 0.45 |
| ▸ | PGGT1B | P53609 | 10/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8098226 | 0.94 | FNTA (0.45) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8089019 | 0.89 | FNTA (0.46) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL446560 | 0.88 | FNTA (0.45) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8097931 | 0.88 | KMT2A (0.51) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8095915 | 0.88 | FNTA (0.45) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8104352 | 0.87 | FNTA (0.43) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8097930 | 0.87 | FNTA (0.46) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8097922 | 0.85 | FNTA (0.51) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8444169 | 0.85 | FNTA (0.51) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8101510 | 0.85 | ALOX12 (0.49) | FNTAFNTBPGGT1BALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6127366-A | ANTICARCINOGENIC OR ANTITUMOR AGENTS | MERCK & CO., INC. (US) | 2000-10-03 | — | — | US | disclosed |